Body Composition

Sermorelin

Sermorelin (GHRH 1-29)

Classic GHRH analog that prompts the pituitary's own GH release

Research Status: Previously FDA-approved; long clinical history GRF 1-29 Geref
Mechanism of Action

How it works

Sermorelin is the bioactive 1-29 fragment of GHRH. It binds pituitary GHRH receptors to stimulate the natural, pulsatile release of growth hormone, preserving physiologic feedback rather than supplying GH directly.

Areas of Research

What the research explores

In published research, Sermorelin has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.

  • Stimulates endogenous, pulsatile GH release
  • Studied for body composition and recovery markers
  • Historically used in GH-deficiency diagnostics
  • Preserves natural feedback regulation
  • Often paired with a GHRP for synergy
Research Highlight

Sermorelin was an approved agent (Geref) used both therapeutically and as a diagnostic test of pituitary GH reserve, giving it a well-documented profile.

Safety Profile

Adverse events & gaps

Well-characterized. Injection-site reactions and flushing most commonly reported. Favorable history.



Stay Informed on
Peptide Research

Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.

No spam. Unsubscribe at any time.